# CYP2C9 polymorphism and warfarin dose requirements

## Metadata
**Authors:** Ann K Daly, Christopher P Day, Guruprasad P Aithal
**Journal:** British Journal of Clinical Pharmacology
**Date:** 2002 Apr
**DOI:** [10.1046/j.1365-2125.2002.01572-6.x](https://doi.org/10.1046/j.1365-2125.2002.01572-6.x)
**PMID:** 11966680
**PMCID:** PMC1874262
**URL:** https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1874262/
**PDF:** [https://pmc.ncbi.nlm.nih.gov/articles/PMC1874262/pdf/bcp0053-0408.pdf](https://pmc.ncbi.nlm.nih.gov/articles/PMC1874262/pdf/bcp0053-0408.pdf)

## References

1. Goldstein JA. Clinical relevance of genetic polymorphisms in the human CYP2C subfamily. Br J Clin Pharmacol. 2001;52:349–355. doi: 10.1046/j.0306-5251.2001.01499.x. 10.1046/j.0306-5251.2001.01499.x.  [DOI](https://doi.org/10.1046/j.0306-5251.2001.01499.x) | [DOI](https://doi.org/10.1046/j.0306-5251.2001.01499.x) | [PMC free article](/articles/PMC2014584/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/11678778/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Br%20J%20Clin%20Pharmacol&title=Clinical%20relevance%20of%20genetic%20polymorphisms%20in%20the%20human%20CYP2C%20subfamily&author=JA%20Goldstein&volume=52&publication_year=2001&pages=349-355&pmid=11678778&doi=10.1046/j.0306-5251.2001.01499.x&)

2. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet. 1999;353:717–719. doi: 10.1016/S0140-6736(98)04474-2.  [DOI](https://doi.org/10.1016/S0140-6736(98)04474-2) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/10073515/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Lancet&title=Association%20of%20polymorphisms%20in%20the%20cytochrome%20P450%20CYP2C9%20with%20warfarin%20dose%20requirement%20and%20risk%20of%20bleeding%20complications&author=GP%20Aithal&author=CP%20Day&author=PJL%20Kesteven&author=AK%20Daly&volume=353&publication_year=1999&pages=717-719&pmid=10073515&doi=10.1016/S0140-6736(98)04474-2&)

3. Yasar U, Eliasson E, Dahl ML, Johansson I, Ingelman-Sundberg M, Sjoqvist F. Validation of methods for CYP2C9 genotyping: Frequencies of mutant alleles in a Swedish population. Biochem Biophys Res Comm. 1999;254:628–631. doi: 10.1006/bbrc.1998.9992.  [DOI](https://doi.org/10.1006/bbrc.1998.9992) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9920790/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Biochem%20Biophys%20Res%20Comm&title=Validation%20of%20methods%20for%20CYP2C9%20genotyping:%20Frequencies%20of%20mutant%20alleles%20in%20a%20Swedish%20population&author=U%20Yasar&author=E%20Eliasson&author=ML%20Dahl&author=I%20Johansson&author=M%20Ingelman-Sundberg&volume=254&publication_year=1999&pages=628-631&pmid=9920790&doi=10.1006/bbrc.1998.9992&)

4. Wang S-L, Huang J-D, Lai M-D, Tsai J-J. Detection of CYP2C9 polymorphism based on the polymerase chain reaction in Chinese. Pharmacogenetics. 1995;5:37–42. doi: 10.1097/00008571-199502000-00004.  [DOI](https://doi.org/10.1097/00008571-199502000-00004) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/7773301/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenetics&title=Detection%20of%20CYP2C9%20polymorphism%20based%20on%20the%20polymerase%20chain%20reaction%20in%20Chinese&author=S-L%20Wang&author=J-D%20Huang&author=M-D%20Lai&author=J-J%20Tsai&volume=5&publication_year=1995&pages=37-42&pmid=7773301&doi=10.1097/00008571-199502000-00004&)

5. Taube J, Halsall D, Baglin T. Influence of cytochrome P-450CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood. 2000;96:1816–1819.  [PubMed](https://pubmed.ncbi.nlm.nih.gov/10961881/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Blood&title=Influence%20of%20cytochrome%20P-450CYP2C9%20polymorphisms%20on%20warfarin%20sensitivity%20and%20risk%20of%20over-anticoagulation%20in%20patients%20on%20long-term%20treatment&author=J%20Taube&author=D%20Halsall&author=T%20Baglin&volume=96&publication_year=2000&pages=1816-1819&pmid=10961881&)

6. Kaminsky LS, Demorais SMF, Faletto MB, Dunbar DA, Goldstein JA. Correlation of human cytochrome P4502c substrate specificities with primary structure – warfarin as a probe. Mol Pharmacol. 1993;43:234–239.  [PubMed](https://pubmed.ncbi.nlm.nih.gov/8429826/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Mol%20Pharmacol&title=Correlation%20of%20human%20cytochrome%20P4502c%20substrate%20specificities%20with%20primary%20structure%20%E2%80%93%20warfarin%20as%20a%20probe&author=LS%20Kaminsky&author=SMF%20Demorais&author=MB%20Faletto&author=DA%20Dunbar&author=JA%20Goldstein&volume=43&publication_year=1993&pages=234-239&pmid=8429826&)

7. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics. 1994;4:39–42. doi: 10.1097/00008571-199402000-00005.  [DOI](https://doi.org/10.1097/00008571-199402000-00005) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/8004131/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenetics&title=Impaired%20(S)-warfarin%20metabolism%20catalysed%20by%20the%20R144C%20allelic%20variant%20of%20CYP2C9&author=AE%20Rettie&author=LC%20Wienkers&author=FJ%20Gonzalez&author=WF%20Trager&author=KR%20Korzekwa&volume=4&publication_year=1994&pages=39-42&pmid=8004131&doi=10.1097/00008571-199402000-00005&)

8. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH. cytochrome P450 oxidoreductase. Pharmacogenetics. 1997;7:203–210. doi: 10.1097/00008571-199706000-00005.  [DOI](https://doi.org/10.1097/00008571-199706000-00005) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/9241660/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenetics&title=The%20R144C%20change%20in%20the%20CYP2C9*2%20allele%20alters%20interaction%20of%20the%20cytochrome%20P450%20with%20NADPH.%20cytochrome%20P450%20oxidoreductase&author=CL%20Crespi&author=VP%20Miller&volume=7&publication_year=1997&pages=203-210&pmid=9241660&doi=10.1097/00008571-199706000-00005&)

9. Aynacioglu AS, Brockmoller J, Bauer S, et al. Frequency of cytochrome P450CYP2C9 variants in a Turkish population and functional relevance for phenytoin. Br J Clin Pharmacol. 1999;48:409–415. doi: 10.1046/j.1365-2125.1999.00012.x.  [DOI](https://doi.org/10.1046/j.1365-2125.1999.00012.x) | [PMC free article](/articles/PMC2014334/) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/10510154/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Br%20J%20Clin%20Pharmacol&title=Frequency%20of%20cytochrome%20P450CYP2C9%20variants%20in%20a%20Turkish%20population%20and%20functional%20relevance%20for%20phenytoin&author=AS%20Aynacioglu&author=J%20Brockmoller&author=S%20Bauer&volume=48&publication_year=1999&pages=409-415&pmid=10510154&doi=10.1046/j.1365-2125.1999.00012.x&)

10. Stubbins MJ, Harries LW, Smith G, Tarbit MH, Wolf CR. Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics. 1996;6:429–439. doi: 10.1097/00008571-199610000-00007.  [DOI](https://doi.org/10.1097/00008571-199610000-00007) | [PubMed](https://pubmed.ncbi.nlm.nih.gov/8946475/) | [Google Scholar](https://scholar.google.com/scholar_lookup?journal=Pharmacogenetics&title=Genetic%20analysis%20of%20the%20human%20cytochrome%20P450%20CYP2C9%20locus&author=MJ%20Stubbins&author=LW%20Harries&author=G%20Smith&author=MH%20Tarbit&author=CR%20Wolf&volume=6&publication_year=1996&pages=429-439&pmid=8946475&doi=10.1097/00008571-199610000-00007&)
